305 related articles for article (PubMed ID: 20202464)
1. An update on the role of interim restaging FDG-PET in patients with diffuse large B-cell lymphoma and Hodgkin lymphoma.
Moskowitz CH; Zelenetz A; Schoder H
J Natl Compr Canc Netw; 2010 Mar; 8(3):347-52. PubMed ID: 20202464
[TBL] [Abstract][Full Text] [Related]
2. An evidence-based review on the value of interim FDG-PET in assessing response to therapy in lymphoma.
Adams HJA; Kwee TC
Semin Oncol; 2017 Dec; 44(6):404-419. PubMed ID: 29935902
[TBL] [Abstract][Full Text] [Related]
3. Current clinical evidence on interim fluorine-18 fluorodeoxy glucose positron emission tomography for advanced-stage Hodgkin lymphoma and diffuse large B-cell lymphoma to predict treatment outcomes.
Terasawa T; Nagai H
Leuk Lymphoma; 2009 Nov; 50(11):1750-2. PubMed ID: 19863179
[TBL] [Abstract][Full Text] [Related]
4. FDG-PET after 1 cycle of therapy predicts outcome in diffuse large cell lymphoma and classic Hodgkin disease.
Kostakoglu L; Goldsmith SJ; Leonard JP; Christos P; Furman RR; Atasever T; Chandramouly A; Verma S; Kothari P; Coleman M
Cancer; 2006 Dec; 107(11):2678-87. PubMed ID: 17063502
[TBL] [Abstract][Full Text] [Related]
5. Combined modality treatment for PET-positive non-Hodgkin lymphoma: favorable outcomes of combined modality treatment for patients with non-Hodgkin lymphoma and positive interim or postchemotherapy FDG-PET.
Halasz LM; Jacene HA; Catalano PJ; Van den Abbeele AD; Lacasce A; Mauch PM; Ng AK
Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):e647-54. PubMed ID: 22607911
[TBL] [Abstract][Full Text] [Related]
6. Early therapeutic response assessment by (18)FDG-positron emission tomography during chemotherapy in patients with diffuse large B-cell lymphoma: isolated residual positivity involving bone is not usually a predictor of subsequent treatment failure.
Ng AP; Wirth A; Seymour JF; Lee M; Hogg A; Januszewicz H; Wolf M; Prince HM; Macmanus M; Hicks RJ
Leuk Lymphoma; 2007 Mar; 48(3):596-600. PubMed ID: 17454604
[TBL] [Abstract][Full Text] [Related]
7. Opportunities and limitations of bone marrow biopsy and bone marrow FDG-PET in lymphoma.
Adams HJ; Nievelstein RA; Kwee TC
Blood Rev; 2015 Nov; 29(6):417-25. PubMed ID: 26113144
[TBL] [Abstract][Full Text] [Related]
8. FDG-PET/CT in the management of lymphomas: current status and future directions.
El-Galaly TC; Villa D; Gormsen LC; Baech J; Lo A; Cheah CY
J Intern Med; 2018 Oct; 284(4):358-376. PubMed ID: 29989234
[TBL] [Abstract][Full Text] [Related]
9. Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in Advanced-stage diffuse large B-Cell lymphoma.
Moskowitz CH; Schöder H; Teruya-Feldstein J; Sima C; Iasonos A; Portlock CS; Straus D; Noy A; Palomba ML; O'Connor OA; Horwitz S; Weaver SA; Meikle JL; Filippa DA; Caravelli JF; Hamlin PA; Zelenetz AD
J Clin Oncol; 2010 Apr; 28(11):1896-903. PubMed ID: 20212248
[TBL] [Abstract][Full Text] [Related]
10. [Resistance to first line chemotherapy treatment in a patient diagnosed of nodular lymphocyte-predominant Hodgkin's lymphoma identified by 18F-FDG PET/CT: diagnostic and therapeutic implications].
Banzo J; Ubieto MA; Giraldo P; Razola P; Prats E; Tardin L; Santapau A; Parra A; Rambalde EF; Velilla J
Rev Esp Med Nucl Imagen Mol; 2012; 31(2):89-92. PubMed ID: 21620527
[TBL] [Abstract][Full Text] [Related]
11. Fluorine-18-fluorodeoxyglucose positron emission tomography for interim response assessment of advanced-stage Hodgkin's lymphoma and diffuse large B-cell lymphoma: a systematic review.
Terasawa T; Lau J; Bardet S; Couturier O; Hotta T; Hutchings M; Nihashi T; Nagai H
J Clin Oncol; 2009 Apr; 27(11):1906-14. PubMed ID: 19273713
[TBL] [Abstract][Full Text] [Related]
12. Role of PET in lymphoma.
Gallamini A; Borra A
Curr Treat Options Oncol; 2014 Jun; 15(2):248-61. PubMed ID: 24619427
[TBL] [Abstract][Full Text] [Related]
13. The value of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography for staging of primary extranodal head and neck lymphomas.
Schrepfer T; Haerle SK; Strobel K; Schaefer N; Hälg RA; Huber GF
Laryngoscope; 2010 May; 120(5):937-44. PubMed ID: 20422687
[TBL] [Abstract][Full Text] [Related]
14. Diffuse Large B-Cell Lymphoma: Prospective Multicenter Comparison of Early Interim FLT PET/CT versus FDG PET/CT with IHP, EORTC, Deauville, and PERCIST Criteria for Early Therapeutic Monitoring.
Minamimoto R; Fayad L; Advani R; Vose J; Macapinlac H; Meza J; Hankins J; Mottaghy F; Juweid M; Quon A
Radiology; 2016 Jul; 280(1):220-9. PubMed ID: 26854705
[TBL] [Abstract][Full Text] [Related]
15. [The role of PET/CT investigation in the management of patients with diffuse large B-cell lymphoma].
Paksi M; Demeter J; Szabó P
Magy Onkol; 2016 Jun; 60(2):108-17. PubMed ID: 27275637
[TBL] [Abstract][Full Text] [Related]
16. 2-[18F]fluoro-2-deoxyglucose positron-emission tomography in staging, response evaluation, and treatment planning of lymphomas.
Specht L
Semin Radiat Oncol; 2007 Jul; 17(3):190-7. PubMed ID: 17591566
[TBL] [Abstract][Full Text] [Related]
17. [Update on the use of FDG-PET/CT in malignant lymphoma].
Terauchi T
Rinsho Ketsueki; 2016; 57(10):2008-2012. PubMed ID: 27795508
[TBL] [Abstract][Full Text] [Related]
18. 18-Fluorodeoxyglucose positron emission tomography/computed tomography for assessment of response to brentuximab vedotin treatment in relapsed and refractory Hodgkin lymphoma.
Kahraman D; Theurich S; Rothe A; Kuhnert G; Sasse S; Scheid C; Dietlein M; Drzezga A; von Bergwelt-Baildon M; Kobe C
Leuk Lymphoma; 2014 Apr; 55(4):811-6. PubMed ID: 23805904
[TBL] [Abstract][Full Text] [Related]
19. The role of FDG-PET in the interim evaluation of therapy response in diffuse large B-cell lymphoma.
Ellmann A
Transfus Apher Sci; 2013 Aug; 49(1):40-2. PubMed ID: 23769694
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of diffuse large B-cell lymphoma patients with 64-slice multidetector computed tomography versus
Gómez León N; Vega G; Rodríguez-Vigil Junco B; Suevos Ballesteros C
Med Clin (Barc); 2018 Oct; 151(7):255-264. PubMed ID: 29705152
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]